Biohaven Pharmaceutical Holding Profit Margin 2016-2022 | BHVN

Current and historical gross margin, operating margin and net profit margin for Biohaven Pharmaceutical Holding (BHVN) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Biohaven Pharmaceutical Holding net profit margin as of June 30, 2022 is -108.04%.
Biohaven Pharmaceutical Holding Annual Profit Margins
Biohaven Pharmaceutical Holding Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $10.873B $0.463B
Biohaven Pharmaceutical is a commercial-stage biotechnology company focused on developing, and commercializing products, primarily in the fields of central nervous system diseases, including neurological and rare disorders.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $150.984B 9.16
GSK (GSK) United Kingdom $59.709B 7.17
Bio-Rad Laboratories (BIO.B) United States $12.433B 27.47
QIAGEN (QGEN) Netherlands $9.383B 15.71
Ginkgo Bioworks Holdings (DNA) United States $4.998B 0.00
Arcus Biosciences (RCUS) United States $1.819B 35.51
Myovant Sciences (MYOV) United Kingdom $1.614B 0.00
Emergent Biosolutions (EBS) United States $1.040B 6.03
ADC Therapeutics SA (ADCT) Switzerland $0.376B 0.00
Zymeworks (ZYME) Canada $0.305B 0.00
Enzo Biochem (ENZ) United States $0.105B 0.00
Gelesis Holdings (GLS) United States $0.081B 0.00
SQZ Biotechnologies (SQZ) United States $0.068B 0.00
Ambrx Biopharma (AMAM) United States $0.041B 0.00